Fig. 4
Therapeutic efficacy of LPA in a SARS-CoV-2-infected hamster model. (A) Schematic diagram of the timeline of LPA administration and analysis in a model of SARS-CoV-2 infection using Syrian hamsters. The diagram shows experimental groups, including the mock infection control, SARS-CoV-2 infection, SARS-CoV-2 + LPA (10 mg/kg), and SARS-CoV-2 + LPA (30 mg/kg), with n = 4 hamsters per group. (B) Percent weight change from baseline in Syrian hamsters over time after SARS-CoV-2 infection with and without LPA administration. The data are expressed as mean ± SD, n = 4 hamsters per group. (C) Representative images of hematoxylin and eosin staining of lung tissue harvested 5 d after SARS-CoV-2 infection with or without LPA (30 mg/kg). Semi-quantitative lung injury scores were graded based on injury criteria described in the Materials and Methods. Data are expressed as mean ± SD, n = 20. ****P< 0.0001. ***P = 0.0002. Scale bar, 200 μm. (D) Representative images of vascular staining with CD31 (green) and TO-PRO-3 (blue) of lung tissue harvested 5 d after SARS-CoV-2 infection with or without LPA (30 mg/kg). Arrows in the SARS-CoV-2 panel indicate areas where endothelial cells have detached from the basement membrane, creating gaps in the vascular lining and resulting in a disorganized vascular structure compared to the continuous endothelial lining seen in control and LPA-treated tissues. Scale bar, 100 μm.
